Analyzing Aralez Pharmaceuticals (ARLZ) and The Competition
Aralez Pharmaceuticals (NASDAQ: ARLZ) is one of 111 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Aralez Pharmaceuticals to similar companies based off the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.
Volatility & Risk
Aralez Pharmaceuticals has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Aralez Pharmaceuticals’ peers have a beta of 0.86, indicating that their average share price is 14% less volatile than the S&P 500.
Institutional and Insider Ownership
23.9% of Aralez Pharmaceuticals shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.7% of Aralez Pharmaceuticals shares are held by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and price targets for Aralez Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aralez Pharmaceuticals Competitors||935||3745||5956||164||2.50|
Aralez Pharmaceuticals currently has a consensus price target of $8.00, indicating a potential upside of 555.74%. All “Pharmaceuticals” companies have a potential upside of 23.53%. Given Aralez Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Aralez Pharmaceuticals is more favorable than its peers.
This table compares Aralez Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aralez Pharmaceuticals Competitors||-3,503.16%||-46.96%||-8.31%|
Earnings & Valuation
This table compares Aralez Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aralez Pharmaceuticals||$87.22 million||-$55.02 million||-0.74|
|Aralez Pharmaceuticals Competitors||$7.98 billion||$2.54 billion||0.78|
Aralez Pharmaceuticals’ peers have higher revenue and earnings than Aralez Pharmaceuticals. Aralez Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently the more affordable than other companies in its industry.
Aralez Pharmaceuticals peers beat Aralez Pharmaceuticals on 7 of the 12 factors compared.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.